Patents by Inventor Nikos Pagratis

Nikos Pagratis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATMENT AND USES FOR CAMKII AND ITS INTERACTION WITH HDACS AND CALPAIN
    Publication number: 20110171196
    Abstract: The present invention provides for methods of treating and cardiac hypertrophy, heart failure, dilated cardiomyopathy or hypertension comprising the use of CaMKII-HDAC binding domains. The present invention discloses not only the fact that CaMKII binds to HDAC4 at a specific site, but that HDAC4 may dimerize with other HDACs. Both events can lead to export of HDACs from the nucleus to the cytoplasm, an event associated with the development of heart disease. Thus the methods of treatment and the screening methods of the present invention are novel attempts to prevent, treat or identify therapies for cardiac hypertrophy, heart failure, dilated cardiomyopathy or hypertension.
    Type: Application
    Filed: January 4, 2011
    Publication date: July 14, 2011
    Applicants: The Board of Regents of the University of Texas System, Gilead Sciences, Inc.
    Inventors: JOHANNES BACKS, BROOKE HARRISON, KHAI HUYNH, KEITH KOCH, TIMOTHY A. MCKINSEY, ERIC OLSON, NIKOS PAGRATIS
  • Methods of treatment and uses for CaMKII and its interaction with HDACs and calpain
    Patent number: 7863414
    Abstract: The present invention provides for methods of treating and cardiac hypertrophy, heart failure, dilated cardiomyopathy or hypertension comprising the use of CaMKII-HDAC binding domains. The present invention discloses not only the fact that CaMKII binds to HDAC4 at a specific site, but that HDAC4 may dimerize with other HDACs. Both events can lead to export of HDACs from the nucleus to the cytoplasm, an event associated with the development of heart disease. Thus the methods of treatment and the screening methods of the present invention are novel attempts to prevent, treat or identify therapies for cardiac hypertrophy, heart failure, dilated cardiomyopathy or hypertension.
    Type: Grant
    Filed: November 17, 2006
    Date of Patent: January 4, 2011
    Assignees: The Board of Regents of the University of Texas Systems, Gilead Sciences, Inc.
    Inventors: Johannes Backs, Brooke Harrison, Khai Huynh, Keith Koch, Timothy A. McKinsey, Eric Olson, Nikos Pagratis
  • Methods of Treatment and Uses for CaMKII and Its Interaction with HDACs and Calpain
    Publication number: 20070142285
    Abstract: The present invention provides for methods of treating and cardiac hypertrophy, heart failure, dilated cardiomyopathy or hypertension comprising the use of CaMKII-HDAC binding domains. The present invention discloses not only the fact that CaMKII binds to HDAC4 at a specific site, but that HDAC4 may dimerize with other HDACs. Both events can lead to export of HDACs from the nucleus to the cytoplasm, an event associated with the development of heart disease. Thus the methods of treatment and the screening methods of the present invention are novel attempts to prevent, treat or identify therapies for cardiac hypertrophy, heart failure, dilated cardiomyopathy or hypertension.
    Type: Application
    Filed: November 17, 2006
    Publication date: June 21, 2007
    Inventors: Johannes Backs, Brooke Harrison, Khai Huynh, Keith Koch, Timothy McKinsey, Eric Olson, Nikos Pagratis
  • High affinity oligonucleotide ligands to growth factors
    Publication number: 20060229273
    Abstract: Methods are described for the identification and preparation of high-affinity nucleic acid ligands to TGF?, PDGF and hKGF. Included in the invention are specific RNA and ssDNA ligands to TGF?1 and PDGF identified by the SELEX method. Also included in the invention are specific RNA ligands to hKGF identified by the SELEX method. Further included are RNA ligands that inhibit the interaction of TGF?1 and hKGF with their receptors and DNA ligands that inhibit the interaction of PDGF with its receptor.
    Type: Application
    Filed: May 31, 2006
    Publication date: October 12, 2006
    Applicant: Gilead Sciences, Inc.
    Inventors: Larry Gold, Nebojsa Janjic, Nikos Pagratis
  • High affinity TGFbeta nucleic acid ligands and inhibitors
    Publication number: 20060084797
    Abstract: Methods are described for the identification and preparation of high-affinity nucleic acid ligands to TGF?2. Included in the invention are specific RNA ligands to TGF?2 identified by the SELEX method. Also included are RNA ligands that inhibit the interaction of TGF?2 with its receptor.
    Type: Application
    Filed: November 23, 2005
    Publication date: April 20, 2006
    Applicant: GILEAD SCIENCES, INC.
    Inventors: Nikos Pagratis, Michael Lochrie, Larry Gold
  • Truncation SELEX method
    Publication number: 20050136474
    Abstract: This invention is directed to a method for identifying nucleic acid ligands by the SELEX method wherein the participation of fixed sequences is eliminated or minimized.
    Type: Application
    Filed: February 15, 2005
    Publication date: June 23, 2005
    Inventors: Nikos Pagratis, Larry Gold, Timur Shtatland, Brenda Javornik
  • Truncation SELEX method
    Patent number: 6855496
    Abstract: This invention is directed to a method for identifying nucleic acid ligands by the SELEX method wherein the participation of fixed sequences is eliminated or minimized.
    Type: Grant
    Filed: July 17, 2001
    Date of Patent: February 15, 2005
    Assignee: Gilead Sciences, Inc.
    Inventors: Nikos Pagratis, Larry Gold, Timur Shtatland, Brenda Javornik
  • High affinity TGFbeta nucleic acid ligands and inhibitors
    Publication number: 20040258656
    Abstract: Methods are described for the identification and preparation of high-affinity nucleic acid ligands to TGF&bgr;2. Included in the invention are specific RNA ligands to TGF&bgr;2 identified by the SELEX method. Also included are RNA ligands that inhibit the interaction of TGF&bgr;2 with its receptor.
    Type: Application
    Filed: March 30, 2004
    Publication date: December 23, 2004
    Inventors: Nikos Pagratis, Michael Lochrie, Larry Gold
  • High affinity TGF&bgr; nucleic acid ligands and inhibitors
    Patent number: 6713616
    Abstract: Methods are described for the identification and preparation of high-affinity nucleic acid ligands to TGF&bgr;2. Included in the invention are specific RNA ligands to TGF&bgr;2 identified by the SELEX method. Also included are RNA ligands that inhibit the interaction of TGF&bgr;2 with its receptor.
    Type: Grant
    Filed: February 23, 2001
    Date of Patent: March 30, 2004
    Assignee: Gilead Sciences, Inc.
    Inventors: Nikos Pagratis, Michael Lochrie, Larry Gold
  • Model cell systems for screening of anti-hypertrophic therapeutics
    Publication number: 20030186289
    Abstract: The present invention identifies the rat muscle cell line H9C2 as a suitable platform for drug screening of potential anti-hypertrophic agents. These cells exhibit gene expression patterns that are characteristic of hypertrophic cells, thus permitting a variety of in vitro screens on candidate drugs to be conducted.
    Type: Application
    Filed: January 21, 2003
    Publication date: October 2, 2003
    Applicant: Myogen, Inc.
    Inventors: Erik Bush, Nikos Pagratis
  • High affinity oligonucleotide ligands to growth factors
    Publication number: 20030180744
    Abstract: Methods are described for the identification and preparation of high-affinity nucleic acid ligands to TGF&bgr;, PDGF and hKGF. Included in the invention are specific RNA and ssDNA ligands to TGF&bgr;1 and PDGF identified by the SELEX method. Also included in the invention are specific RNA ligands to hKGF identified by the SELEX method. Further included are RNA ligands that inhibit the interaction of TGF&bgr;1 and hKGF with their receptors and DNA ligands that inhibit the interaction of PDGF with its receptor.
    Type: Application
    Filed: August 19, 2002
    Publication date: September 25, 2003
    Applicant: GILEAD SCIENCES, INC.
    Inventors: Larry Gold, Nebojsa Janjic, Nikos Pagratis
  • High affinity TGFbeta nucleic acid ligands and inhibitors
    Publication number: 20030064943
    Abstract: Methods are described for the identification and preparation of high-affinity nucleic acid ligands to TGF&bgr;2. Included in the invention are specific RNA ligands to TGF&bgr;2 identified by the SELEX method. Also included are RNA ligands that inhibit the interaction of TGF&bgr;2 with its receptor.
    Type: Application
    Filed: February 23, 2001
    Publication date: April 3, 2003
    Inventors: Nikos Pagratis, Michael Lochrie, Larry Gold
  • Truncation selex method
    Publication number: 20030003461
    Abstract: This invention is directed to a method for identifying nucleic acid ligands by the SELEX method wherein the participation of fixed sequences is eliminated or minimized.
    Type: Application
    Filed: July 17, 2001
    Publication date: January 2, 2003
    Applicant: Gilead Sciences, Inc.
    Inventors: Nikos Pagratis, Larry Gold, Timur Shtatland, Brenda Javornik
  • High affinity TGf&bgr; nucleic acid ligands and inhibitors
    Patent number: 6346611
    Abstract: Methods are described for the identification and preparation of high-affinity nucleic acid ligands to TGF&bgr;2. Included in the invention are specific RNA ligands to TGF&bgr;2 identified by the SELEX method. Also included are RNA ligands that inhibit the interaction of TGF&bgr;2 with its receptor.
    Type: Grant
    Filed: July 29, 1999
    Date of Patent: February 12, 2002
    Assignee: Gilead Sciences, Inc.
    Inventors: Nikos Pagratis, Michael Lochrie, Larry Gold
  • Truncation selex method
    Patent number: 6261774
    Abstract: This invention is directed to a method for identifying nucleic acid ligands by the SELEX method wherein the participation of fixed sequences is eliminated or minimized.
    Type: Grant
    Filed: March 24, 1999
    Date of Patent: July 17, 2001
    Assignee: Gilead Sciences, Inc.
    Inventors: Nikos Pagratis, Larry Gold, Timur Shtatland, Brenda Javornik
  • High affinity oligonucleotide ligands to growth factors
    Patent number: 6207816
    Abstract: Methods are described for the identification and preparation of high-affinity nucleic acid ligands to TGF&bgr;, PDGF and hKGF. Included in the invention are specific RNA and ssDNA ligands to TGF&bgr;1 and PDGF identified by the SELEX method. Also included in the invention are specific RNA ligands to hKGF identified by the SELEX method. Further included are RNA ligands that inhibit the interaction of TGF&bgr;1 and hKGF with their receptors and DNA ligands that inhibit the interaction of PDGF with its receptor.
    Type: Grant
    Filed: May 11, 1998
    Date of Patent: March 27, 2001
    Assignee: NeXstar Pharmaceuticals, Inc.
    Inventors: Larry Gold, Neboisa Janjic, Nikos Pagratis
  • High affinity TGF.beta. nucleic acid ligands and inhibitors
    Patent number: 6124449
    Abstract: Methods are described for the identification and preparation of high-affinity nucleic acid ligands to TGF.beta.. Included in the invention are specific RNA ligands to TGF.beta.1 identified by the SELEX method. Also included are RNA ligands that inhibit the interaction of TGF.beta.1 with its receptor.
    Type: Grant
    Filed: March 23, 1998
    Date of Patent: September 26, 2000
    Assignee: NeXstar Pharmaceuticals, Inc.
    Inventors: Larry Gold, Nikos Pagratis
  • High affinity nucleic acid ligands of cytokines
    Patent number: 6028186
    Abstract: Methods are described for the identification and preparation of high-affinity nucleic acid ligands to cytokines. Included in the invention are specific nucleic acid ligands to IFN-gamma, IL-4, IL-10, TNF-alpha, and RANTES.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: February 22, 2000
    Assignee: NeXstar Pharmaceuticals, Inc.
    Inventors: Diane Tasset, Nikos Pagratis, Sumedha Jayasena, Larry Gold
  • High affinity nucleic acid ligands of cytokines
    Patent number: 5972599
    Abstract: Methods are described for the identification and preparation of high-affinity nucleic acid ligands to cytokines. Included in the invention are specific nucleic acid ligands to IFN-gamma, IL-4, IL-10, TNF-alpha, and RANTES.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: October 26, 1999
    Assignee: NeXstar Pharmaceuticals, Inc.
    Inventors: Diane Tasset, Nikos Pagratis, Sumedha Jayasena, Larry Gold
  • High affinity HKGF nucleic acid ligands and inhibitors
    Patent number: 5846713
    Abstract: Methods are described for the identification and preparation of high-affinity nucleic acid ligands to hKGF. Included in the invention are specific RNA ligands to hKGF identified by the SELEX method. Also included are RNA ligands that inhibit the interaction of hKGF with its receptor.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: December 8, 1998
    Assignee: Nexstar Pharmaceuticals, Inc.
    Inventors: Nikos Pagratis, Larry Gold